Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Future Rises After Positive Annual Outlook

Mon, 01st Jul 2019 10:49

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------DS Smith, up 1.7%. The paper and packaging firm said it completed the sale of two packaging businesses in north west France and in Portugal to Memphis, Tennessee-based peer International Paper for EUR63 million. DS Smith said the sale honours the commitment made to the European Commission in relation to the clearance of its acquisition of Spanish packaging firm Europac, which completed in January. Last month, DS Smith had said financial 2019, which ended on April 30, was a "year of good delivery" overall, with "substantial" progress being made overseas and the integration of Europac was going well. Fellow packaging firms Smurfit Kappa and Mondi were up 2.6% and 1.7%, respectively. ----------FTSE 100 - LOSERS----------Fresnillo, down 2.9%. The Mexican gold miner was tracking spot gold prices lower, quoted at USD1,390.28 an ounce, down sharply from USD1,411.62 late Friday. Last week, gold had touched a six-year high of USD1,438.63. Additionally, Fresnillo on Monday said it has decided to align tax treatment for all of the company's underground mining operations, resulting in a USD8.0 million impact on profit for the six months to June-end. Shares in midcap gold miners Centamin and Hochschild Mining also were being hurt by the lower gold price, down 2.2% and 1.7%, respectively.----------International Consolidated Airlines Group, down 1.2%. Bernstein downgraded the airlines operator to Market Perform from Outperform. ----------FTSE 250 - WINNERS----------Future, up 9.0%. The digital media and publishing firm said full-year results will be ahead of expectations, underpinned by good audience growth within the Media division and the continued strong performance of recent acquisitions. The guidance was also attributed to a continuation of positive trends seen in the first half. Future's financial year ends September and will report annual results in November. "Future has a platform which enables it to monetise specialist content through a mixture of e-commerce, getting content users to click through to partnered retailers, events and online advertising. The plan is to feed newly-acquired assets into this platform. Newspaper and magazine publishers continue to battle falling sales and have struggled to get readers to pay for their relatively generic content, but consumers have shown a greater willingness to pay for specialist and niche content which they are unable to get elsewhere," said AJ Bell's Russ Mould.----------FTSE 250 - LOSERS----------John Laing Group, down 1.0%. Barclays started coverage on the infrastructure project investor at Equal Weight. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Tiziana Life Sciences, up 14%. The biotechnology company noted a study in which a drug similar to Foralumab was shown to delay the onset of type-1 diabetes. The phase two study of Teplizumab, an anti-CD3 antibody similar to Foralumab being developed by Provention Bio, was published in the New England Journal of Medicine. Type-1 diabetes is caused by the immune system's T cells attacking insulin-producing cells in the body. Anti-CD3 antibodies like Tiziana's Foralumab and Provention Bio's Teplizumab suppress the immune system to prevent this from happening. Teplizumab is derived from mice and was injected intravenously in patients whose relatives already have type 1 diabetes. Of the 76 patients evaluated, 72% were under 18. The patients were randomised to receive either a 14-day course of Teplizumab or placebo and tested at six-month intervals. At the end of the Teplizumab trial, 57% of participants treated with the drug had not developed diabetes compared to 28% on the placebo.----------OTHER MAIN MARKET AND AIM - LOSERS----------Hurricane Energy, down 17%. The oil and gas explorer said it will abandon and plug the Warwick Deep well after it did not produce at commercial rates. Hurricane had drilled the offshore North Sea well to 1,964 metres, with results indicating a 712-metre horizontal section of fractured basement reservoir. However, initial analysis suggests the well found a "poorly" connected part of the fracture network within the oil column, and the well produced at non-commercial rates. Following plugging and abandoning Warwick Deep, Hurricane will move the rig to the Lincoln Crestal wall, the second of three wells on the Greater Warwick Area.----------

More News
18 Jul 2016 08:46

Tiziana Life Buys Gene Samples Of Long-Lifed Sardinian Community

Read more
24 Jun 2016 09:49

WINNERS & LOSERS SUMMARY: Gold, Dollar Exposure Rewarded Post-Brexit

Read more
24 Jun 2016 07:44

UPDATE: UK Chemicals And Pharmaceuticals Must "Look To Future"

Read more
23 Jun 2016 15:08

UK Shareholder Meetings Calendar - Next 7 Days

Read more
7 Jun 2016 08:27

Tiziana Life Sciences 2015 Loss Widens As It Progresses Candidates

Read more
1 Jun 2016 14:49

Tiziana partnership scoops innovation award

(ShareCast News) - Clinical stage biotechnology company Tiziana Life Sciences was celebrating on Wednesday, after its partnership with researchers at Cardiff University collected a fresh award. The AIM-traded company said the partnership, which has led to the development of a potential new drug for

Read more
19 May 2016 10:13

Tiziana Life Sciences Says Its Antibody Foralumab Featured In Review

Read more
4 Apr 2016 07:36

Tiziana Life Sciences Appoints Tiziano Lazzaretti As Finance Chief

Read more
4 Apr 2016 07:32

Tiziana Life Sciences appoints new CFO

(ShareCast News) - Tiziana Life Sciences has appointed Tiziano Lazzaretti as Chief Financial Officer, effective immediately. Confirming the move on Monday, the AIM-listed biotechnology company said the appointment was not a board level position. Lazzaretti has extensive experience in the healthcare

Read more
13 Jan 2016 09:53

Tiziana Life Sciences Raises Funds Via Convertible Loan Note Issue (ALLISS)

Read more
11 Jan 2016 09:17

Tiziana To Focus Foralumab Development On Two Clinical Applications

Read more
8 Jan 2016 08:35

Tiziana reveals possible new anti-cancer molecule

(ShareCast News) - Tiziana Life Sciences revealed the great strides it had made in the quest for cancer-fighting drugs this week, as part of its research partnership with the Cardiff University / Prifysgol Caerdydd. The AIM-listed biotechnology company, which focuses on targeted drugs to treat disea

Read more
8 Jan 2016 07:54

Tiziana Identifies New Potential Cancer Drug With Cardiff University

Read more
9 Dec 2015 09:20

Tiziana Life Sciences Appoints James Tripp Chief Operating Officer

Read more
8 Dec 2015 10:04

Tiziana Life Sciences Raises GBP3.8 Million Via Convertible Note Issue (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.